311 related articles for article (PubMed ID: 33866918)
1. The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death.
Duan XC; Peng LY; Yao X; Xu MQ; Li H; Zhang SQ; Li ZY; Wang JR; Feng ZH; Wang GX; Liao A; Chen Y; Zhang X
Drug Deliv; 2021 Dec; 28(1):800-813. PubMed ID: 33866918
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo.
Duan XC; Yao X; Zhang S; Xu MQ; Hao YL; Li ZT; Zheng XC; Liu M; Li ZY; Li H; Wang JR; Feng ZH; Zhang X
Int J Nanomedicine; 2019; 14():195-204. PubMed ID: 30636872
[TBL] [Abstract][Full Text] [Related]
3. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug.
Song P; Yao X; Zhong T; Zhang S; Guo Y; Ren W; Huang D; Duan XC; Yin YF; Zhang SS; Zhang X
Oncotarget; 2016 Jul; 7(30):48467-48480. PubMed ID: 27366947
[TBL] [Abstract][Full Text] [Related]
5. Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity.
Sethuraman SN; Singh MP; Patil G; Li S; Fiering S; Hoopes PJ; Guha C; Malayer J; Ranjan A
Theranostics; 2020; 10(8):3397-3412. PubMed ID: 32206098
[No Abstract] [Full Text] [Related]
6. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.
Tang X; Rao J; Yin S; Wei J; Xia C; Li M; Mei L; Zhang Z; He Q
Eur J Pharm Sci; 2019 Jan; 127():161-174. PubMed ID: 30366077
[TBL] [Abstract][Full Text] [Related]
8. Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy.
Hu N; Xue H; Zhang T; Fan Y; Guo F; Li Z; Huo M; Guan X; Chen G
Biomed Pharmacother; 2024 May; 174():116482. PubMed ID: 38520866
[TBL] [Abstract][Full Text] [Related]
9. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
[TBL] [Abstract][Full Text] [Related]
10. 4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent.
Hufnagel S; Xu H; Colemam MF; Valdes SA; Liu KA; Hursting SD; Cui Z
Cancer Chemother Pharmacol; 2022 Jan; 89(1):59-69. PubMed ID: 34698902
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer.
Qin T; Xu X; Zhang Z; Li J; You X; Guo H; Sun H; Liu M; Dai Z; Zhu H
Nanotechnology; 2020 Sep; 31(36):365101. PubMed ID: 32434167
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
13. Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death.
Tu K; Deng H; Kong L; Wang Y; Yang T; Hu Q; Hu M; Yang C; Zhang Z
ACS Appl Mater Interfaces; 2020 Apr; 12(14):16018-16030. PubMed ID: 32192326
[TBL] [Abstract][Full Text] [Related]
14. Drug-binding albumins forming stabilized nanoparticles for co-delivery of paclitaxel and resveratrol: In vitro/in vivo evaluation and binding properties investigation.
Zhao Y; Cai C; Liu M; Zhao Y; Wu Y; Fan Z; Ding Z; Zhang H; Wang Z; Han J
Int J Biol Macromol; 2020 Jun; 153():873-882. PubMed ID: 32169451
[TBL] [Abstract][Full Text] [Related]
15. Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations.
Ye J; Li R; Yang Y; Dong W; Wang Y; Wang H; Sun T; Li L; Shen Q; Qin C; Xu X; Liao H; Jin Y; Xia X; Liu Y
J Nanobiotechnology; 2021 Jul; 19(1):199. PubMed ID: 34225762
[TBL] [Abstract][Full Text] [Related]
16. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
17. Chronic chemotherapy with paclitaxel nanoparticles induced apoptosis in lung cancer in vitro and in vivo.
Zhao X; Fan J; Wu P; Wei C; Chen Q; Ming Z; Yan J; Yang L
Int J Nanomedicine; 2019; 14():1299-1309. PubMed ID: 30863062
[TBL] [Abstract][Full Text] [Related]
18. The Ability of Clinically Relevant Chemotherapeutics to Induce Immunogenic Cell Death in Squamous Cell Carcinoma.
He Z; Jing X; Dai X; Bao L; Yang X; Xiong Y; Li M
Front Biosci (Landmark Ed); 2024 Apr; 29(4):158. PubMed ID: 38682206
[TBL] [Abstract][Full Text] [Related]
19. The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy.
Zhang Y; Akhil V; Seo HS; Park HR; Kim SH; You SH; Liu Z; Kim SY; Sultonova RD; Min JJ; Hong Y
Theranostics; 2024; 14(3):1195-1211. PubMed ID: 38323311
[TBL] [Abstract][Full Text] [Related]
20. An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy.
Hu Z; Zheng B; Xu J; Gao S; Lu W
Nanotechnology; 2020 May; 31(29):295101. PubMed ID: 32203949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
